trial

Antipsychotic Effects on Brain Function in Schizophrenia

NCTId NCT01913327
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Terminated
Enrollment 4 (actual)
Sponsored by University of California Riverside at C.I. Trials, Inc.-Inland Empire
Primary completion 2017-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Terminated
Enrollment
4 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-04
Primary completion
2017-01
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
AripiprazoleRisperidonemodafinil

Sponsors

University of California Riverside at C.I. Trials, Inc.-Inland EmpireLead Sponsor
The Dana FoundationCollaborator

Sites

1 total
San Francisco, United States

Facts & assertions

4 sourced
Enrollment
4
Phase
PHASE4
Primary Completion Date
2017-01
Status
TERMINATED
relationships
The graph out of here
drug
Aripiprazole
drug
Risperidone
drug
modafinil
drug
lead_sponsor
University of California Riverside at C.I. Trials, Inc.-Inland Empire
company
collaborator
The Dana Foundation
company
indication
Schizophreniform Disorder
indication
Schizoaffective Disorder
indication
Psychotic Disorders
indication